18 results
P
patients with concomitant erectile dysfunction (ED) and stress urinary incontinence (SUI)
I/C
synchronous surgery for concomitant ED and SUI, asynchronous surgery, surgery solely for ED or SUI
O
reoperation rates
P
5,812,381
I/C
Long-term exposure to PM10 (including solely estimated exposure to PM10 from studies using PM2.5)
O
Increased risk of CKD (RR 1.08, 95 %CI 1.04-1.11) with considerable heterogeneity (I2 = 64.3%)
P
patients who underwent HIHR
I/C
hybrid incisional hernia repair (HIHR), laparoscopic incisional hernia repair (LIHR)
O
perioperative complications, intra-operative complications, postoperative prevalence of surgical site occurrences (SSOs), surgical site occurrences requiring interventions (SSOPIs)
P
patients
I/C
1L polyethylene glycol plus ascorbic acid with adjuvant drug regimens (1L PEG-AA, lower volume), 2L polyethylene glycol plus ascorbic acid (2L PEG-A, low volume)
O
efficacy of bowel preparation, tolerability, complication rate
P
children and adolescents
I/C
attachment, non-attachment
O
somatoform symptoms
P
infants from birth to 24 months of age
I/C
non-pharmacological strategies
O
success rate of obtaining usable magnetic resonance images
P
infant, bronchiolitis, hospitalization
I/C
respiratory syncytial virus (RSV), rhinovirus (RV), clinical presentation
O
oxygen supplementation, fever, wheezing on auscultation, atopic traits, infection severity
P
patients with cancer treatment-related lymphoedema (CTRL)
I/C
vascularised lymph node transfer (VLNT), no comparison, observational study
O
reducing upper limb (UL) or lower limb (LL) volume and cellulitis episodes
P
ZRAS, placebo, BzRAs
I/C
ZRAS, placebo, BzRAs
O
sleep quality, number of adverse events
P
Africa population
I/C
valvular heart surgery, no data or evidence
O
overall mortality 10.48%, 30-day mortality 4.59%